Journal of Biomedical Materials Research Part B Applied Biomaterials · 2024 · 11 citations · 34 references
PharmacyPharmaceuticsPharmacologyBioavailabilityDrug DeliveryPharmaceutical FormulationDiabetic Foot Ulcer CareFoot Ulcer PreventionFormulation Effects On BioavailabilitySolubility OptimizationUlcer ManagementBox-behnken DesignsControlled Drug ReleaseDiabetic Foot DisordersDiabetic Foot Ulcer PharmacotherapyDrug Loading EffectsStorage Stability EvaluationVesicle Release KineticsVesicle Size Control
Abstract Kaempferol (KMP) belong to flavonoid class have developed in ethosomal formulation and were evaluated for their potential to treat diabetic foot ulcers. Even though ethosomes are highly deformable, they can pass through human skin intact. KMP ethosomes were formulated using the cold method and optimized by Box–Behnken design (BBD) (three‐factor, three‐level (3 3 )). The formulation variables used for optimization are drug concentration of KMP, soylecithin content, and ethanol percentage. The optimized formulation was examined using transmission electronic microscopy (TEM), differential scanning calorimetry (DSC), Fourier transform infrared (FTIR) spectroscopy, in‐vitro release, ex‐vivo permeation studies, and storage stability. The optimized KMP ethosomes was found to have vesicle size (VS) of 283 ± 0.3 nm and zeta potential (ZP) of −29.67 ± 0.3 mV, polydispersity index (PDI) of 0.36, % entrapment efficiency (%EE) of 91.02 ± 0.21%, drug loading (%) of 46.23 ± 2.5% followed by good storage stability at 4°C/60 ± 5% RH. In vitro drug release of optimized KMP ethosomes was 88.2 ± 2.75%, which was approximately double when compared with pure KMP release, that is 49.9 ± 1.89%. The release kinetics for optimized KMP ethosomes follows the Korsmeyer–Peppas model. An apparent permeation coefficient of 356.25 ± 0.5 μg/cm 2 was determined and compared with pure KMP (118.46 ± 0.3 μg/cm 2 ) for 24 h. According to the study, ethosomes can be a cutting‐edge strategy that offers a new delivery method for prolonged and targeted distribution of KMP in a variety of dosage forms including oral, topical, transdermal, and so forth.
34
DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles
Yong Zhang, Meirong Huo, Jianping Zhou et al. · The AAPS Journal · 2010 · 1.6K citations · Full text
W. Patrick Walters, Mark A. Murcko · Advanced Drug Delivery Reviews · 2002 · 441 citations
Yutao Liu, Jie Pan, Si‐Shen Feng · International Journal of Pharmaceutics · 2010 · 168 citations
Thasleem Moolakkadath, Mohd. Aqil, Abdul Ahad et al. · Artificial Cells Nanomedicine and Biotechnology · 2018 · 159 citations · Full text